Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: A surviving animal model

Melanoma Research

Volumn 7, Issue 1, 1997, Pages 19-26

  Wu, Z Y ^a   Roberts, M S ^a   Parsons, P G ^b   Smithers, B M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

blood flow; isolated rat hindlimb perfusion; melanoma; surviving animal model

Indexed keywords

MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIMB PERFUSION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; SURVIVAL; TUMOR BLOOD FLOW; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE MODELS, ANIMAL; HINDLIMB; HUMANS; MELANOMA; MELPHALAN; NEOPLASM TRANSPLANTATION; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031047084     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199702000-00004     Document Type: Article

References (31)

1. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
2. Hartley JW, Fletcher WS. Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with L-phenylalanine mustard. J Surg Oncol 1987; 36: 170-174.
3. Baas PC. Isolated regional perfusion in the treatment of local recurrence stallitosis and intransit metastasis of melanomas of the extremities. Reg Cancer Treat 1988; 1: 33-38.
4. Stehlin JS. Heat as an adjuvant in the treatment of advanced melanoma. An immune stimulant? Houston Med J 1988; 4: 61-64.
5. Hafstrom L, Rudenstan CM, Blomquist E, Ingoar C. Jonsson PE, Lagerlof B, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091-2094.
6. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-233.
7. Parkins WM, Ravdin RG, Cogins PF. Exploratory study of vascular occlusion and perfusion techniques for the localization of action of cytotoxic drugs. Am Coll Surg, Surg Forum 1959; 9: 591-596.
8. Shingleton WW, Reeves JW, Keppel RA, Mahaley S, Taylor HM. Studies on abdominal organ perfusion for cancer chemotherapy. Ann Surg 1960; 151: 741-748.
9. Ryan RF, Winblad JN, Hottinger GC, Creech O Jr. Effects of various perfusates in isolated vascular beds using extracorporeal circuit. Am Coll Surg, Surg Forum 1959; 9: 194-198.
10. Turner FW, Tod DM, Francis GJ, Greenhill BJ, Couves CM. The technique for isolation-perfusion of the rat hindlimb. Cancer Res 1962; 22: 49-54.
11. Kakutani T, Yamaoka K, Hashida M, Sezaki H. A new method for assessment of drug disposition in muscle: application of statistical moment theory to local perfusion system. J Pharmacokinet Biopharmacol 1985; 13: 609-631.
12. Côté C, Thibault MC, Vallieres J. Effect of endurance training and chronic isoproterenol treatment on skeletal muscle sensitivity to norepinephrine. Life Sci 1985; 37: 695-701.
13. Colquhoun EQ. Hettiarachchi M, Ye JM, Richter EA. Atniat AJ, Rattigan S, et al. Vasopressin and angiotensin II stimulate oxygen uptake in the perfused rat hindlimb. Life Sci 1988; 43: 1747-1754.
14. Shiota M, Masum S. Effect of norepinephrine on consumption of oxygen in perfused skeletal muscle from cold-exposed rats. Am J Physiol 1988; 254: E482-E489.
15. Wu ZY, Rivory LP, Roberts MS. Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: I. Characterisation of the physiology with changing perfusate flow, protein content and temperature using statistical moment analysis. J Pharmacokinet Biopharmacol 1993; 21: 653-688.
16. Heatherington AC, Rowland M. Estimation of reference spaces in the perfused rat hindlimb. Eur J Pharmacol Sci 1993; 2: 261-268.
17. Wu ZY, Cross SE, Roberts MS. Influence of physicochemical parameters of solutes and perfusate flow rate on their distribution in the isolated perfused rat hindlimb using the impulse±response technique. J Pharmacol Sci 1995; 84: 1020-1027.
18. Scott RN, Blackie R, Kerr DJ, Hughes J. Burnside G. MacKie RM. et al. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992; 28A: 1811-1813.
19. Clark J. Grabs AJ, Parsons PG, Smithers BM, Addison RS. Roberts MS. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994; 4: 365-370.
20. Parsons PG, Caner FB, Morrison L, Mary SR. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1982; 41: 1525-1530
21. Goss PD, Parsons PG. The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res 1977; 37: 152-155.
22. Wu ZY, Thompson MJ, Grabs AJ, Addison RS, Smithers BM. Roberts MS. High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. J Chromatogr (B) 1995; 673: 267-279.
23. Brown JA. Renal microvasculature of the rainbow trout. Salmo gairdneri: scanning electron microscopy of corrosion casts of glomeruli. Anat Rec 1985; 213: 505-513.
24. Manusama ER, Nooijen PTGA, Staavast J. Durante NMC. Marquet RL, Eggermont AMM. Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83: 551-555.
25. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximising efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 199; 4: 45-50.
26. Lejeune FJ, Ghanem GE. A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limb based on exchangeable blood volume determine. Cancer Res 1987; 47: 639-643.
27. Hafstrom L, Hugander A, Jonsson PE, Westling H. Ehrsson H. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 1984; 68: 867-872.
28. Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Das Gupta TK. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985; 45: 1885-1889.
29. Ontell SJ, Makowka L, Trager J, Mazzaferro V, Ove P, Starzl TE. Pharmacologic modulation of experimental postischemic hepatic function. Ann Surg 1989; 209: 200-210.
30. Brass CA, Crawford JM, Narciso J, Gollan JL. Hypoxic liver injury and the ameliorating effects of fructose: the 'glucose paradox' revisited. Am J Physiol 1992; 263 (Gastrointest Liver Physiol 26): G293-G300.
31. Hamamoto I, Nemoto EM, Evans RW, Mischinger HJ, Fujita S, Murase N, et al. Rat liver lipids during ex vivo warm and cold ischemia and reperfusion. J Surg Res 1993; 55: 382-389.